Autoimmune & autoinflammatory
Graft-versus-host disease chronic
Chronic graft-versus-host disease is the donor immune system waging a slow campaign against its new host after stem cell transplant - a multi-organ autoimmune-like illness, and the leading cause of late transplant complications.
Key points
The essentials at a glance.
What to look out for, which tests matter, who treats it, and what usually happens next.
-
Onset typically months to years after allogeneic stem cell transplant - vigilance never fully retires
-
Favourite targets: skin (tightening, rashes), mouth and eyes (dryness, ulcers), liver, lungs (bronchiolitis obliterans), joints and fascia
-
The lung form is the most feared: falling spirometry may be the only early sign - home spirometry programmes exist for a reason
-
First-line treatment remains corticosteroids; ruxolitinib and other newer agents now serve steroid-refractory disease
-
Every organ complaint after transplant deserves the question: could this be GVHD?
Understanding it
About Graft-versus-host disease chronic.
The same donor T-cells that cure the leukaemia by attacking residual malignant cells can turn on healthy tissue, and the chronic form borrows the clothing of classic autoimmune diseases: skin that tightens like scleroderma, eyes and mouth as dry as Sjögren's, liver enzymes climbing like PBC, fascia stiffening joints, and small airways scarring closed in the pattern called bronchiolitis obliterans - the complication where months matter and breathlessness arrives late. Patients juggle this alongside infection risk, since both the disease and its treatment suppress immunity.
Modern care is systematised: standardised organ-by-organ scoring at transplant clinic reviews, scheduled pulmonary function testing to catch the lung form pre-symptomatically, topical therapies that spare systemic immunosuppression for limited disease, and a genuinely expanded drug arsenal - ruxolitinib, ibrutinib and belumosudil among them - for steroid-refractory cases. For patients, the operational rules are simple and non-negotiable: report new symptoms in any organ early, keep every monitoring appointment, and maintain the infection prophylaxis and vaccination schedule the transplant team prescribes. In many parts of the UK, a routine NHS referral to the relevant specialist clinic currently means waiting many months - sometimes more than a year for the rarest conditions - whereas an initial appointment with a private consultant is typically available within around two weeks, with investigations arranged soon after.
Frequently asked
Common questions about Graft-versus-host disease chronic.
Quick, plain-English answers to what people ask us most.
-
What is chronic graft-versus-host disease?
Chronic graft-versus-host disease (GvHD) is a long-term complication that can occur after an allogeneic stem cell or bone marrow transplant, in which the donor's immune cells recognise the recipient's own tissues as foreign and attack them. It typically develops from around three months after transplant, though it can occur later, and can affect multiple organs including the skin, mouth, eyes, liver, lungs and gut. It requires ongoing specialist management, sometimes for a prolonged period.
-
What causes chronic GvHD?
It occurs when donor immune cells (specifically T-cells) transplanted along with the stem cells recognise the recipient's tissues as different from the donor's own and mount an immune attack against them. The degree of genetic mismatch between donor and recipient influences the risk, along with other factors such as previous acute GvHD, donor and recipient age, and the specific transplant conditioning used. Prevention strategies during and after transplant aim to reduce this risk, though it cannot be eliminated entirely.
-
What symptoms does chronic GvHD cause?
Symptoms vary depending on which organs are affected, and can include skin changes resembling scleroderma or lichen planus, dry mouth and eyes, joint stiffness, liver function abnormalities, breathing problems, and digestive symptoms. It can affect just one organ system or multiple systems simultaneously, and severity ranges from mild to significantly disabling. Regular monitoring after transplant helps detect chronic GvHD at an early, more manageable stage.
-
Is chronic GvHD dangerous?
Yes, it can significantly affect quality of life and, in severe cases, cause serious organ damage and increased susceptibility to infection due to ongoing immunosuppressive treatment. However, with appropriate specialist management, many people achieve good control of symptoms and reasonable quality of life over time. Regular specialist follow-up is important to monitor and adjust treatment as the condition evolves.
-
How is chronic GvHD treated?
Treatment typically involves immunosuppressive medications, most commonly corticosteroids initially, sometimes combined with other immune-modulating treatments for more resistant or extensive disease. Treatment is tailored to which organs are affected and how severely. This is generally a long-term treatment process, sometimes requiring gradual tapering of medication over months to years as the condition improves.
-
When should I see a specialist?
Anyone who has had a stem cell or bone marrow transplant should have regular follow-up with their transplant team to monitor for chronic GvHD, and should report any new symptoms promptly rather than waiting for a scheduled appointment. This is usually managed within your existing transplant follow-up programme; a private haematology consultation can be arranged within about 2 weeks if additional or earlier specialist input is wanted.